SEC Filing Summary: Collegium Pharmaceutical, Inc. (COLL)
Business Context and Reporting Period
This Form 8-K, dated August 6, 2026, reports the financial results for the quarterly period ended June 30, 2026. The filing serves as a notification of the release of a press release (Exhibit 99.1) and an earnings presentation (Exhibit 99.2) containing the detailed operational and financial data.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the attached press release and earnings presentation, which are furnished but not filed within the body of this 8-K document.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached exhibits for comparative analysis.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, and risk factors are contained within the attached earnings presentation and press release. This 8-K summary does not include specific details on contingencies or unusual items.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures for the quarter ended June 30, 2026.
- Examine Exhibit 99.2 (Earnings Presentation) for updated financial guidance and strategic outlook.
- Verify year-over-year and quarter-over-quarter performance trends not explicitly stated in this filing.
- Confirm the status of the company's cash position and debt obligations as detailed in the full financial statements.